A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease (NCT07326709)
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Who can join: Review the eligibility criteria below.
Location: University of CA San Diego — La Jolla, California
Age range: 21 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (60 Sites)
Showing the first 25 of 60 sites.
- University of CA San Diego — La Jolla, California
- UC Davis Health System — Sacramento, California
- Stanford Healthcare — Stanford, California
- CenExcel Rocky Mtn Clin Research — Englewood, Colorado
- U Conn Health — Farmington, Connecticut
- Georgetown University — Washington D.C., District of Columbia
- University Of South Florida — Tampa, Florida
- Parkinsons-Movement Disorder Ctr — Chicago, Illinois
- Indiana University Health — Indianapolis, Indiana
- University of Iowa Health Care — Iowa City, Iowa
- University of Kansas Hospital — Fairway, Kansas
- Henry Ford Health System — Detroit, Michigan
- Trinity Health Michigan — Grand Rapids, Michigan
- Albany Medical College — Albany, New York
- UBMD Neurology — Buffalo, New York
- Columbia University Irving Medical — New York, New York
- Universi of Rochester School of Med — Rochester, New York
- University Of NC At Chapel Hill — Chapel Hill, North Carolina
- Duke University Health System — Durham, North Carolina
- Cleveland Clinic Foundation — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- University Of Pittsburgh — Pittsburgh, Pennsylvania
- Veracity Neuroscience LLC — Memphis, Tennessee
- Vanderbilt University Medical CenterX — Nashville, Tennessee
- TX Movement Disorder Spec PLLC — Georgetown, Texas
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Huntington Disease
- Neurobiological Predictors of Huntington's Disease (PREDICT-HD) — Iowa City, Iowa
- Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease — Nashville, Tennessee
- GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Birmingham, Alabama
- An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) — Clayton,
- Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) — Charlottesville, Virginia
- Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease — Rochester, New York
Explore by condition: All Huntington Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.